chronic pain; limiting mobility; leg muscle pain; the pain/ myalgias are limiting her mobility; pain in neck; severe pain in her arms, legs; This spontaneous case was reported by a patient family member or friend and describes the occurrence of PAIN IN EXTREMITY (severe pain in her arms, legs), NECK PAIN (pain in neck), PAIN (chronic pain), MOBILITY DECREASED (limiting mobility) and PAIN IN EXTREMITY (leg muscle pain) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 010A21A and 028L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Carotid artery dissection in 2000 and Supraventricular tachycardia in 2012. Concurrent medical conditions included Hypertension since 2000 and Hypercholesterolemia. Concomitant products included ATORVASTATIN CALCIUM (LIPITOR) from an unknown date to 01-May-2021 for Cholesterol, SPIRONOLACTONE and FISH OIL for Heart disorder, DILTIAZEM and CARVEDILOL for Supraventricular tachycardia.   On 30-Jan-2021 at 3:30 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Feb-2021 at 10:00 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 03-Mar-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced PAIN IN EXTREMITY (severe pain in her arms, legs). On 05-Mar-2021, the patient experienced NECK PAIN (pain in neck). On 07-Mar-2021, the patient experienced PAIN IN EXTREMITY (leg muscle pain). 07-Mar-2021, the patient experienced MYALGIA (the pain/ myalgias are limiting her mobility). On an unknown date, the patient experienced PAIN (chronic pain). an unknown date, the patient experienced MOBILITY DECREASED (limiting mobility). The patient was treated with PREDNISONE from 11-Apr-2021 to 19-Apr-2021 at a dose of 40 mg; PREDNISONE from 11-Apr-2021 to 19-Apr-2021 at a dose of 30 mg; PREDNISONE from 11-Apr-2021 to 19-Apr-2021 at a dose of 20 mg; PREDNISONE from 11-Apr-2021 to 19-Apr-2021 at a dose of 15 mg; PREDNISONE from 11-Apr-2021 to 19-Apr-2021 at a dose of 12.5 mg; PREDNISONE from 11-Apr-2021 to 19-Apr-2021 at a dose of 10 mg; PREDNISONE from 11-Apr-2021 to 19-Apr-2021 at a dose of 7.5 UNK; PREDNISONE from 11-Apr-2021 to 19-Apr-2021 at a dose of 5 mg; PREDNISONE from 11-Apr-2021 to 19-Apr-2021 at a dose of 2.5 mg; NAPROXEN at a dose of 500 mg twice a day and ESOMEPRAZOLE MAGNESIUM (NEXIUM [ESOMEPRAZOLE MAGNESIUM]) at a dose of 20 mg. On 16-Mar-2021, NECK PAIN (pain in neck) had resolved. At the time of the report, PAIN IN EXTREMITY (severe pain in her arms, legs), PAIN (chronic pain), MOBILITY DECREASED (limiting mobility), PAIN IN EXTREMITY (leg muscle pain) and MYALGIA (the pain/ myalgias are limiting her mobility) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 22-Mar-2021, C-reactive protein: 1.2mg/l (normal) Normal. On 07-Apr-2021, C-reactive protein: 2.2mg/l (normal) normal. On 30-Apr-2021, C-reactive protein: 65.2mg/l (normal) normal. In 2021, Blood test: normal (normal) normal.         The reporter stated, the patient has had issues for over a month without signs that the pain will dissipate.   Action taken with mRNA-1273 in response to the events was not applicable.  Patients lab data include: sedimentation rate on 3/22 - 6 mm/H. (Result-Unknown) Sedimentation rate on 4/7 - 4 mm/H.(Result-Unknown) Sedimentation rate - 4/30 - 6 mm/H. (Result-Unknown) Rheumatoid factor - 4/17 - < 13 IU/ml Aldolase - 3/30 - 5.7 U/L   Most recent FOLLOW-UP information incorporated above includes: On 04-May-2021: Follow-up received contains lab data and treatment product details.